

2022 #37

October 14, 2022


INSIDE:

U.S. to Begin Screening Air Travelers Arriving from Uganda for Ebola .2
WORD IN WASHINGTON2
RESEARCH IN BRIEF3
PEOPLE4
MEMBER NEWS.....4
GLOBAL NEWS5
COMPANY NEWS6
CALENDAR7
POSITIONS.....8

ADRP Launches DonatingBlood.org

ADRP, an International division of America's Blood Centers (ABC), unveiled the new DonatingBlood.org website this week. This site is a “first-of-its-kind” [resource](#) that is designed “to connect-first time and returning blood donors with donation sites and other resources from across the blood community. The site aims to be a clearinghouse of information designed specifically for donors to make giving blood easier than ever at a critical time.”

DonatingBlood.org features a “comprehensive locator tool that allows new and returning donors to find the donation location, including both permanent donation sites and mobile blood drives, closest to them, regardless of blood center. The site also has donor stories, multimedia resources educating first-time donors about what to expect when giving blood, and social media tools allowing people to spread the word about the importance of donating.”



Theresa Pina, president of ADRP and vice president of Operations at the Gulf Coast Regional Blood Center added in a news release announcing the site, “A lot of organizations are doing critical work relaying the importance of donation and where to find their sites to give blood. That often causes people to search across multiple websites just to find the donation location closest to them. We’re proud to launch DonatingBlood.org to make it easier for people to find information, locate donation centers from across the blood community, and become lifelong donors.” ABC Chief Executive Officer Kate Fry, MBA, CAE stated, “Although 65 percent of the U.S. population is eligible to donate blood, just three percent currently do. We need to increase that number dramatically and reach younger and more diverse donors to create a reliable blood supply. This website will make it easier than ever for more people to learn about the importance of donation, find the blood center closest to them, and help save lives.”

DonatingBlood.org also features [Vein to Vein: The Science of Blood Donation](#), a high school education program, and other specific resources segmented for [donors](#), [media](#), and [educators](#).

(Source: ADRP [News Release](#), 10/13/22) ♦

U.S. to Begin Screening Air Travelers Arriving from Uganda for Ebola

On September 26th, the World Health Organization (WHO) provided an [update](#) from health authorities in Uganda on an outbreak of Ebola after 18 confirmed cases in the region and 18 probable cases. The WHO reported that 23 deaths [are] likely linked to the outbreak with five confirmed. This is the first Ebola disease outbreak caused by Sudan virus (SUDV) in Uganda since 2012 stated the WHO. According to the organization, “[o]f the total confirmed and suspected cases, 62 percent are female, and 38 percent are male. There are currently 13 confirmed cases hospitalized. The median age of the cases is 26 years (range 1 year to 60 years). A cumulative number of 223 contacts have been listed.”

The *New York Times* [reported](#) on October 6th that the U.S. planned to have “travelers who had been to Uganda redirected to airports where they can be screened for the virus and warned physicians to be alert for potential cases. [At that time], [n]o cases of Ebola had yet been reported outside Uganda, but the virus — which spreads only through contact with bodily fluids and is not airborne — is highly contagious. American officials are watching the Uganda outbreak closely because there are no approved vaccines or treatments for the type of Ebola virus causing the outbreak there.”

The U.S. Centers for Disease Control and Prevention (CDC) and the WHO have not classified the affected area as having “widespread transmission of Ebola virus,” at this time, which would trigger donor interventions in the U.S. The U.S. Food and Drug Administration (FDA) [guidance](#) requires that “in the event that one or more countries is classified by CDC as having widespread transmission of Ebola virus, your donor history questionnaire (DHQ), including your full-length and abbreviated DHQ, and accompanying materials, must incorporate elements to assess prospective donors for symptoms of recent or current illness with Ebola virus infection or disease, and travel to, or residence in, an area endemic for Ebola virus in accordance with 21 CFR 630.10(e)(2).”

(Sources: [Ebola virus disease – Uganda](#), 9/26/22; *New York Times*, [U.S. to begin screening air passengers from Uganda for Ebola](#), 10/6/22) ◆

WORD IN WASHINGTON

U.S. Department of Health and Human Services (HHS) Secretary Xavier Becerra, JD has [extended](#) the COVID-19 public health emergency (PHE) effective October 13, 2022. The PHE began in January 2020 and has been extended in 90-day increments as required by law. It allows several pandemic response measures and flexibility to continue. This includes multiple donor deferral changes made by the FDA early in the pandemic, such as reducing blood donor deferral for men who have sex with other men (MSM) to three months, which are currently in effect until 60 days after the end of the PHE. HHS has committed to providing no less than 60-day notice prior to terminating the PHE declaration.

(Source: HHS COVID-19 PHE [Renewal](#), 10/13/22)

The Administration for Strategic Preparedness and Response’s (ASPR) Technical Resources, Assistance Center, and Information Exchange (TRACIE) within HHS is hosting a webinar on November 7th titled “Infection Prevention and Control: Incorporating Lessons Learned in Managing Special Pathogens.” During the webinar attendees will hear speakers share their perspectives on how [ASPR’s] “approach to outbreaks has changed since the pandemic began. [Speakers will also] address issues such as infection prevention for healthcare workers and patients and mitigating disease spread [as speakers] highlight newly developed tools and resources.” The free webinar will take place at 2 p.m. Though registration has closed, a recording of the webinar will be available on the ASPR TRACIE website under “In the News” within 24 hours of the conclusion of the webinar. Slides may also be requested [here](#) when available.

(Source: ASPR TRACIE Webinar [Announcement](#), 10/11/22) ◆

RESEARCH IN BRIEF

Rates of Hemolysis of Red Cells Made from Lipemic Donations. A study in *Vox Sanguinis* investigated “the *in vitro* quality of red blood cells (RBC) prepared from lipemic whole blood donations.” The authors explained that “[I]lipemic (n = 54) and non-lipemic (n = 20; controls) plasma [and RBC] components were selected based on visual inspection...The mean body mass index (BMI) of donors whose donations were lipemic was not significantly different to that of the control donors: 29.2 + 4.1 kg/m² and 28.6 + 6.7 kg/m², respectively (p = 0.6746)...There were no significant differences in the coagulation properties of the lipemic and control plasma...The mean triglyceride concentration in the lipemic plasma was fourfold higher than the control plasma, while there was no difference in the cholesterol concentration between the two groups...There was no difference in the glucose concentrations between groups; however, the lactate concentration was higher in the lipemic group than in the control group.” The investigators noted that “[t]he mean hemolysis was not significantly different between the two groups, and neither was the proportion of RBC components with hemolysis above 0.4 percent (p = 0.494)...However, the lactate dehydrogenase (LDH) concentration in RBC prepared from lipemic whole blood donations was significantly higher than in control RBC on Day 21 of storage...By expiry, there was no longer a significant difference in LDH...There were no significant differences in potassium release, adenosine triphosphate (ATP) and microparticles (MPs) numbers in the lipemic and control RBC.” The study found that “RBC hemolysis at expiry did not correlate with donor BMI, however, there was a weak but significant correlation with triglyceride concentration (p=0.0017) in the corresponding plasma samples. The authors explained that [t]he data from this study show that there were some small but significant differences in lactate production and LDH in RBC prepared from lipemic and non-lipemic whole blood donations, and these differences are unlikely to be biologically relevant...Although there is a slight trend toward higher hemolysis in RBC from lipemic donations, this was not significant.” The authors concluded that “RBCs produced from lipemic whole blood donations are still suitable for transfusion, providing [they are not too turbid to perform] mandatory infectious disease screening.”

Citation: Winter, K.M., Webb, R.G., Marks, D.C. [Red cells manufactured from lipaemic whole blood donations: Do they have higher haemolysis?](#) *Vox Sang.* 2022.

Contributed by Richard Gammon, MD, Medical Director at OneBlood 

We Welcome Your Letters

The *ABC Newsletter* welcomes letters from its readers on any blood-related topic that might be of interest to ABC members. Letters should be kept relatively short and to the point, preferably about a topic that has recently been covered in the *ABC Newsletter*. Letters are subject to editing for brevity and good taste and published after editorial review. Please send letters to the Editor at newsletter@americasblood.org or fax them to (202) 899-2621. Please include your correct title and organization as well as your phone number. The deadline for letters is Wednesday to make it into the next newsletter.

The *ABC Newsletter* (ISSN #1092-0412) is published by America's Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2022 by America's Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher. (ABC members need not obtain prior permission if proper credit is given.)

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognize the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies and programs that increase awareness about the need for blood donation; and serve as a thought-leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America's Blood Centers

Chief Executive Officer: Kate Fry
Chief Medical Officer: Rita Reik
Editor: Mack Benton
Subscriptions Manager: Leslie Maundy
Annual Subscription Rate: \$390

Send subscription queries to memberservices@americasblood.org
America's Blood Centers
1717 K St. NW, Suite 900, Washington, DC 20006
Phone: (202) 393-5725
Send news tips to newsletter@americasblood.org.



PEOPLE



Scott Jones, PhD has been [named](#) senior vice president and chief scientific officer at BioBridge Global. Dr. Jones has been with the organization since 1999 and previously served as vice president of Scientific Affairs. According to a BioBridge news release, in his new role he will be “leading the organization’s growing research and development activities.” BioBridge Chief Executive Officer Martin Landon added, “[t]his promotion recognizes Scott both for the many contributions he has made to building our research and development [R&D] capabilities and for his strategic thought leadership. That includes numerous custom assay scientific projects, building the R&D team, and serving as the key technical executive in the Community Labs initiative during the COVID-19 pandemic.” Dr Jones “earned his bachelor’s degree in microbiology from Texas A&M University and a doctorate in microbiology from UT Health San Antonio. He did post-doctorate work at the Texas Center for Infectious Disease, where he was the Director of the TB-

RFLP Laboratory. He has authored and delivered numerous oral and poster presentations at annual meetings for the South Central Association of Blood Banks (SCABB), the Association for the Advancement of Blood & Biotherapies (AABB), and the Congress of International Society of Blood Transfusion.”

(Source: BioBridge Global [News Release](#), 10/7/22) ◆

MEMBER NEWS

Blood Assurance recently [presented](#) the Scott Hamilton CARES Foundation with a check for \$14,000. The financial contribution is the result of a partnership where “Blood Assurance donated \$10 to Hamilton’s foundation for every donor who gave blood at a site in Middle Tennessee,” according to the *Williamson Herald*. Blood Assurance Regional Director Gerald Antoine told the media outlet, “[t]his partnership is very important because the Scott Hamilton Cares Foundation does cancer research and is continuously working for cures and ways to better serve patients that are dealing with cancer. Blood and blood products, especially platelets, are a part of a cancer patient’s therapy and recovery. They need those products. Melding both CARES Foundation and Blood Assurance helps us serve those cancer patients much better and also allows [Blood Assurance] to make monetary contributions to Hamilton’s research foundation to help find cures for cancer. Blood Assurance Chief Operating Officer Christopher Swafford, MBA added, “[i]t’s something that couldn’t be done without all of our donors, our advocates, and all of the people in the community who really got behind this. We are just so blessed to be a part of this community and to be able to support [Hamilton’s] foundation.”



Photo courtesy of the *Williamson Herald*.

(Source: *Williamson Herald*, [Blood Assurance donates more than \\$14K to Scott Hamilton CARES Foundation](#), 10/7/22) ◆

ABC Calendar of Events

ABC offers a variety of meetings, workshops and virtual opportunities for education and networking as well as participation in ABC business. The [calendar of events](#) includes annual and summer meetings, board meetings, workshops, and webinars, and details will be updated as confirmed. We look forward to your support and participation!



Upcoming ABC and ADRP Webinars – Don't Miss Out!

- **ABC New Benchmarking Platform, Service Fee Survey Results Webinar** – October 18 from 2-3 PM EDT. More information available to ABC members in MCN 22-086 including a link to join the webinar. Contact [us](#) for a copy of the MCN.
- **ABC National HOSA Partnership Webinar** – October 19 from 2-3 PM EDT. More information available to ABC members in MCN 22-083 including a link to join the webinar. Contact [us](#) for a copy of the MCN.
- **ABC Reverse Mentoring Webinar** – November 2 from 2-3 PM EDT. More information coming soon!
- **ADRP 2022 International Showcase** – November 9 from 1-2:30 PM EST. [Registration](#) is open and free to all.
- **ABC Blood Product Inventory Management: Donor Center & Hospital Transfusion Service Perspectives** – November 15 from 3-4:30 PM EST. More information coming soon!
- **ABC Scientific, Medical, and Technical Journal Club Webinar** – December 7 from 3-4 PM EST. More information coming soon!

GLOBAL NEWS

The World Health Organization (WHO) African Region [published](#) a “Status Report on Blood Availability, Safety and Quality.” The report provides updates and information on:

- [c]ritical indicators of availability and access to safe and quality-assured blood products;
- [m]easure[s] the level of the implementation of resolutions from the Regional Committee for Africa and the World Health Assembly;
- [c]ompare[s] the trends with the status reported before the COVID-19 pandemic; and
- [i]dentif[ies] the gaps needing priority attention.”

The report includes data from 39 of 47 member states that were invited to participate. The WHO described highlights from analysis of the report as, “data revealed that about two thirds of the countries had developed all the critical blood safety documents in 2020. Thirty-six countries (92.3 percent) had a blood policy, 33 (84.6 percent) a strategic plan, and 23 (59 percent) had legislation. Thirty-five countries (89.7 percent) reported national standards and eight mentioned at least one accredited blood service. Out of the 39 participants, 24 countries (61.5 percent) received external funding in 2020. More than half of the needed blood units are collected. Out of 39 countries, 16 participants had more than 80 percent of voluntary nonremunerated blood donation (VNRBD), and 19 had less than 50 percent of VNRBD. The COVID-19 pandemic impacted the blood supply in the Region and hampered progress towards meeting blood needs, mainly during the first 5 months of 2020. The donation rate before and after the COVID-19 pandemic was 4.9/1000 and 5.9/1000 respectively.

(Source: WHO African Region [Status Report on Blood Availability, Safety and Quality](#), 10/10/22)

(continued on page 6)

GLOBAL NEWS (continued from page 5)

NHS Blood and Transplant, the national blood provider for England and transplant services for the United Kingdom (UK), “[issued](#)” an alert for donors this week as their blood supplies waned. According to the *BBC*, “[t]he NHS usually has six days’ worth of blood to use for operations and transfusions, but levels are currently due to fall below two.” Following the alert, NHSBT reported to the news agency that:

- “166,000 people visited the blood-donor website, the most since the pandemic began; and
- 7,500 people registered as new donors, the most in the past 20 years.”

NHSBT attributed the blood shortage to challenges brought on by the COVID-19 pandemic such as “staff shortages and sickness, and a change in people’s behavi[o]r means they are less likely to visit donation cent[ers] in towns and cities.”

(Source: *BBC*, [Public responds to NHS amber alert over donor blood stocks](#), 10/13/22) ♦

COMPANY NEWS

The U.S. Food and Drug Administration (FDA) has [accepted](#) **BioMarin Pharmaceutical Inc.**’s resubmission of a biologics license application (BLA) for its investigational gene therapy candidate to treat adults with severe hemophilia A. According to a news release from the company, the BLA resubmission “incorporates [BioMarin’s] responses to all deficiencies identified in the FDA Complete Response (CR) Letter from August 2020. [It also] includes a substantial amount of data from the [gene therapy’s] clinical development program, the most extensively studied gene therapy for severe hemophilia A, including two-year outcomes from all study participants in the global GENER8-1 Phase III study. The GENER8-1 Phase III study demonstrated stable and durable bleed control, including a reduction in the mean annualized bleeding rate (ABR) and the mean annualized Factor VIII infusion rate. In addition, the data package includes supportive evidence from five years of follow-up from the 6e13 vg/kg dose cohort in the ongoing Phase I/II dose escalation study. The BLA also includes a proposed long-term extension study following all clinical trial participants for up to 15 years, as well as a post-approval registry study to follow patients dosed in a real-world setting.” If approved the investigational gene therapy would be the “first gene therapy in the U.S. for the treatment of severe hemophilia A.”

(Source: BioMarin Pharmaceutical Inc. [News Release](#), 10/12/22)

Vir Biotechnology, Inc. [announced](#) that it has been awarded a multi-year contract by the U.S. Department of Health and Human Services (HHS)’ Biomedical Advanced Research and Development Authority (BARDA) “to address influenza and potentially other infectious disease threats.” The Vir news release explains that BARDA will specifically “invest approximately \$55 million initially for the ongoing and rapid development of [an investigational prophylactic monoclonal antibody (mAb)] designed to protect against seasonal and pandemic influenza. This includes a Phase II pre-exposure prophylaxis trial expected to begin in the second half of 2022 with initial data anticipated in mid-2023...The BARDA agreement also outlines potential support for Vir’s clinical development of additional future pandemic influenza mAbs, as well as the potential development of up to 10 emerging infectious disease or Chemical, Biological, Radiological, and Nuclear medical countermeasure candidates.”

(Source: Vir Biotechnology, Inc. [News Release](#), 10/4/22)

Pfizer Inc. and **BioNTech SE** shared preliminary [data](#) from an ongoing phase II/III clinical trial of its bivalent COVID-19 vaccine that targets Omicron BA.4/BA.5. According to a news release from the companies, “[a] 30-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent vaccine demonstrated a substantial increase in the Omicron BA.4/BA.5 neutralizing antibody response above pre-booster levels

(continued on page 7)

COMPANY NEWS (continued from page 6)

based on sera taken 7 days after administration, with similar responses seen across individuals aged 18 to 55 years of age and those older than 55 years of age. When comparing responses in individuals older than 55 years of age who received either the bivalent vaccine, or the original vaccine, a 30- μ g booster dose of the Original Pfizer-BioNTech COVID-19 Vaccine elicited more limited increases in the neutralizing antibody response against the Omicron BA.4/BA.5 variants...[T]hese data suggest a 30- μ g booster dose of the Omicron BA.4/BA.5-adapted bivalent vaccine is anticipated to provide better protection against the Omicron BA.4 and BA.5 variants than the original vaccine for younger and older adults. The Omicron BA.4 and BA.5-adapted bivalent vaccine was well tolerated with early data indicating a favorable safety profile, similar to that of the original vaccine.”

(Source: Pfizer Inc. and BioNTech SE [News Release](#), 10/13/22) 

CALENDAR

***Note to subscribers:** Submissions for a free listing in this calendar (published weekly) are welcome. Send information to newsletter@americasblood.org. (For a more detailed announcement in the weekly “Meetings” section of the newsletter, please include program information.)*

2022

Oct. 18. **ABC New Benchmarking Platform, Service Fee Survey Results Webinar.** More information available in MCN 22-086. Contact [us](#) for a copy of the MCN.

Oct. 19. **ABC National HOSA Partnership Webinar.** More information available in MCN 22-083. Contact [us](#) for a copy of the MCN.

Oct. 24-25. **U.S. Department of Health and Human Services (HHS) Tick-Borne Disease Working Group Meeting (Virtual).** More information available [here](#).

Nov. 6-7. **Association for the Advancement of Blood & Biotherapies (AABB) Annual Meeting (Virtual).** More information available [here](#).

Nov. 9. **ADRP International Showcase (Virtual).** [Registration](#) is open and free. More information available [here](#).

Nov. 15-16. **The Biomedical Advanced Research and Development Authority (BARDA) Industry Day (Virtual).** More details available [here](#).

Nov. 17. **U.S. Department of Health and Human Services Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) Meeting (Virtual).** More details available [here](#).

Dec. 7. **(HHS) Tick-Borne Disease Working Group Meeting (Virtual).** More information available [here](#).

2023

Mar. 6-8. **ABC Annual Meeting, Washington, D.C.** More information coming soon.

April. 24-28. **ABC Blood Center Advocacy Week.** More information coming soon.

May 9-11. **2023 ADRP Conference, Charlotte, N.C.** More information coming soon.

Sept. 17-20. **American Association of Tissue Banks Annual Meeting, National Harbor, Md.** More information available [here](#).

Oct. 14-17. **AABB Annual Meeting, Nashville, Tenn.** More information available [here](#). 



CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC institutional members. There are charges for non-members: \$139 per placement for ABC Newsletter subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

POSITIONS

Technical Director. Central California Blood Center based in Fresno, seeks ideal candidate for the position of Technical Director. Specialist in Blood Banking (SBB ASCP) preferred, at least 10 years blood donor testing and component manufacturing experience required, including leadership position(s). California CLS license strongly preferred. Seeking a proven leadership-skilled individual who builds teams, collaborates, mentors, and innovates. The Technical Director is responsible for our blood donor testing laboratory, blood components manufacturing, phase III clinical trial research and biomanufacturing, immunohematology reference lab, and providing technical guidance to donor services when needed. Current area of responsibility includes over 25 FTE. Responsible for designing programs and tactics in line with company strategic goals, participating in senior leadership, assuring all processes and SOP are in compliance with state and federal regulations and AABB. Collaborates with Medical Director and other senior leaders to assure compliance, effectiveness, and positive culture within the company. Excellent salary and benefits package. How to apply: www.donateblood.org/career-opportunities/

Director of Hospital Services and Manufacturing. Blood Bank of Alaska is seeking a director to oversee our Hospital Services and Manufacturing Department in Anchorage, AK. This position is responsible for ensuring our manufacturing and distribution areas are operating in compliance with applicable government regulations, and accrediting agency standards. Also ensuring there is a dedicated focus on the production and distribution of quality products while providing the highest level of customer service. The Director will participate as a member of the blood bank's management team in planning, program formulation, and decision making for the functions and technical support of the manufacturing and distribution of blood products. The incumbent for this role must possess excellent conceptual, communication and analytical skills. Must understand general workflow processes and equipment used in a medical facility. The right candidate will have a bachelor's degree in a relevant field (required) and five years of supervisory experience in a highly regulated, fast-paced, and compliance-driven environment (preferred). If you meet the above qualifications, please apply by sending your resume to: mcannon@bbak.org. For more information about the Blood Bank of Alaska, please visit our website at <https://www.bloodbankofalaska.org>.

Business Development Representatives and Donor Recruitment Managers. The Blood Connection is hiring experienced Business Development Representatives and Donor Recruitment Managers in the Savannah, Charlotte, and Asheville areas. Please reach out to Sean Hair at shair@thebloodconnection.org for more information.

Territory Sales Consultant (Fort Smith, Arkansas, USA). Territory Sales Consultants must develop new partnerships with targeted decision makers in community organizations, educational and religious institutions, and businesses to gain support in meeting the needs for volunteer blood donors. Responsibilities include organizing and promoting blood donation events; assessing, developing, and implementing strategic/tactical plans to achieve recruitment objective/goals. She/he is expected to develop a customer-focused culture that will result in successful community partnerships and donation awareness. Identify opportunities for growth within current group base, and facilitate a plan to achieve growth percentage for total unit collection within territory. Book recurring blood drives for the following year. Develop and maintain relationships with key accounts. Give presentations in order to promote blood collection. Identify and provide feedback on issues regarding customer needs/requirements, customer issues/concerns and satisfaction, competitor activities/strategies, etc. Interact effectively and professionally with team members and all internal/external contacts. Qualifications: Associate/Bachelor's degree preferred, one to three years sales related experience, public speaking/presentation experience preferred, excellent communication skills, and valid driver's license with access to vehicle. Salary Range: Competitive salary, commission plan, and excellent benefits package including health, dental, vision, and life insurance, 401(k), paid time off, and holiday pay. How to apply: <http://arkbi.org/careers/>.

Territory Sales Consultant (Oklahoma City, Oklahoma, USA). Territory Sales Consultants must develop new partnerships with targeted decision makers in community organizations, educational and religious institutions, and businesses to gain support in meeting the needs for volunteer blood donors. Responsibilities include organizing and promoting blood donation events; assessing, developing, and implementing strategic/tactical plans to achieve recruitment objective/goals. She/he is expected to develop a customer-focused culture that will result in successful community partnerships and do

(continued on page 9)



POSITIONS (continued from page 8)

nation awareness. Identify opportunities for growth within current group base and facilitate a plan to achieve growth percentage for total unit collection within territory. Book recurring blood drives for the following year. Develop and maintain relationships with key accounts. Give presentations to promote blood collection. Identify and provide feedback on issues regarding customer needs/requirements, customer issues/concerns and satisfaction, competitor activities/strategies, etc. Interact effectively and professionally with team members and all internal/external contacts. Qualifications: Associate/Bachelor's degree preferred, one to three years sales related experience, public speaking/presentation experience preferred, excellent communication skills, and valid driver's license. Salary Range: Competitive salary with commission plan and excellent benefits package including health, dental, vision, and life insurance, 401(k), paid time off, and \$500 bonus after 6 months and \$1,000 bonus after 1 year! How to apply: <http://obi.org/careers/>.

President and CEO (MEDIC Regional Blood Center). MEDIC Regional Blood Center is seeking a President and CEO. MEDIC, located in Knoxville, Tennessee, is a financially successful not-for-profit, independent blood center serving 25 hospitals in 22 counties throughout East Tennessee and Southern Kentucky. The preferred candidate is one who has demonstrated leadership experience in the blood industry, although related healthcare experience may be considered. The successful candidate must possess strategic planning abilities and have strong interpersonal skills to maintain the external relationships that have been developed. This position is accountable for operational goals and providing direction to the organization. The ideal candidate should possess an ability to build cohesive, high-performing teams focused on the achievement of MEDIC's goals. Candidates must be able to formulate a clear vision of how best to respond to challenges of the blood industry and do so in a highly regulated environment. The ideal candidate must have a least ten years of progressive managerial experience and hold a bachelor's degree from an accredited college or university. A graduate degree such as MBA, MHA, or equivalent is preferred. Please submit cover letter, resume, and salary requirements to Katy Stout, HR Manager at kstout@medicblood.org. The deadline for applications is **October 31, 2022**.

Director, Regulatory Affairs and Public Policy. America's Blood Centers (ABC), North America's largest network of community-based, independent blood programs, is seeking a **Director, Regulatory Affairs and Public Policy**. The position is a key role for ABC and will provide the successful candidate an opportunity to lead a strategic area of work while benefitting from the flexibility of a fully remote office environment. The Director, Regulatory Affairs and Public Policy will assist in

the development, implementation, execution, and advancement of the ABC Advocacy Agenda before federal agencies and other stakeholders. Responsibilities: Analyze, evaluate, communicate, and track the impact of new regulatory and science, medical, technical (SMT) developments on ABC member centers, including working with members and staff in the development of policy positions, public statements, and comment letters and responses to information requests from federal agencies. Build strategic relationships as a liaison with appropriate staff at FDA and other federal agencies as necessary (including HHS, OSHA, DOL, NCR, CDC, DOD, and others), and non-governmental industry partners. Serve as an ABC representative and spokesperson to industry coalitions. Conduct routine operational and ad hoc member surveys that support the ABC Advocacy Agenda. Work includes the creation of survey forms and protocols, analysis of data, and preparation and dissemination of reports. Educational Requirements: Bachelor's required. Experience, Knowledge, Skills, and Abilities: Seven plus years of experience with public policy and regulatory affairs, preferably with FDA. Click [here](#) to view the full job description. Interested applicants should send a cover letter and resume to careers@americasblood.org.

Manager of Technical Services. The Blood Connection is looking for a Manager of Technical Services in Morrisville, NC. This is a new role that will be responsible for supervising and managing the daily operations of the technical departments: Hospital Services, Component Manufacturing/Biologics Processing, and Immunohematology Reference Laboratory. We offer a generous benefits package including a great 401k match, tuition reimbursement, yearly increases, company bonus, cell phone stipend, and 30 days PTO. Join our team and help make an impact in your community today! Relocation assistance offered. Click [here](#) to apply.

Medical Director (Gulf Coast Regional Blood Center). Reporting to the Chief Medical Officer, this individual will assist in providing oversight of operational and implementation expertise across multiple areas of a large community blood center. Areas of responsibility include medical oversight of selection and care of donors, collection, processing, and testing of blood, and disease notification. In addition, this individual will provide guidance for The Blood Center's transfusion service activities and cellular therapy programs, as well as serving as a liaison with medical staff in the community to address transfusion concerns and assure the appropriate utilization of blood products. Requirements: Doctor of Medicine or Doctor of Osteopathy degree from an accredited university with at least four years of combined education and experience in blood banking/transfusion medicine or related field. Board certified or board -eligible in Pathology, Hematology, or related field. Specialty

(continued on page 10)



POSITIONS (continued from page 9)

training and/or certification in Blood Banking, Hematology, or a similar related field is highly desirable. Eligible for medical license in the state of Texas. Applicants with additional medical or management experience in apheresis related to cellular therapy and transplant are strongly encouraged to apply. Click [here](#) to apply. ♦